journal
Journals Japanese Journal of Clinical O...

Japanese Journal of Clinical Oncology

https://read.qxmd.com/read/38654608/projection-of-the-number-of-new-cases-of-bladder-cancer-in-the-world
#1
JOURNAL ARTICLE
Sumiyo Okawa, Laureline Gatellier
No abstract text is available yet for this article.
April 23, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38651188/potential-utility-of-pretreatment-serum-mirnas-for-optimal-treatment-selection-in-advanced-high-grade-serous-ovarian-cancer
#2
JOURNAL ARTICLE
Takashi Uehara, Juntaro Matsuzaki, Hiroshi Yoshida, Yuto Ogawa, Junichiro Miura, Hitoshi Fujimiya, Yusuke Yamamoto, Junpei Kawauchi, Satoko Takizawa, Kan Yonemori, Hiromi Sakamoto, Ken Kato, Mitsuya Ishikawa, Takahiro Ochiya
OBJECTIVE: The primary treatment of patients with advanced ovarian cancer is selected from whether primary debulking surgery or neoadjuvant chemotherapy. We investigated whether pretreatment serum microRNA profiles are useful for selecting patients with advanced high-grade serous ovarian cancer who obtain better outcomes from undergoing primary debulking surgery or neoadjuvant chemotherapy. METHODS: Consecutive patients with clinical stage IIIB-IVB and serum microRNA data were selected...
April 22, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38651176/predictive-factors-of-nivolumab-plus-ipilimumab-treatment-efficacy-in-metastatic-renal-cell-carcinoma-patients
#3
JOURNAL ARTICLE
Kojiro Ohba, Hiromi Nakanishi, Ken Kawada, Yuichiro Nakamura, Kensuke Mitsunari, Tomohiro Matsuo, Yasushi Mochizuki, Ryoichi Imamura
OBJECTIVE: Nivolumab plus ipilimumab is a recommended first-line therapy regimen for metastatic renal cell carcinoma. However, it is not clear which patient characteristics are associated with its effectiveness. METHODS: We retrospectively examined 67 metastatic renal cell carcinoma patients treated with nivolumab plus ipilimumab as a first-line therapy in multiple institutions from September 2018 to August 2022. We analyzed the relationships between survival outcomes and patient-related variables, including paraneoplastic symptoms...
April 22, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38643356/safety-and-effectiveness-of-clofarabine-in-japanese-patients-with-relapsed-refractory-acute-lymphoblastic-leukaemia-a-post-marketing-surveillance-study
#4
JOURNAL ARTICLE
Hirotaka Kazama, Satoshi Nishina, Takeshi Seto
OBJECTIVE: Clofarabine is used to treat acute lymphoblastic leukaemia, but evidence of its safety and effectiveness in Japanese patients is limited. We evaluated the safety and effectiveness of clofarabine in patients with relapsed/refractory acute lymphoblastic leukaemia in real-world clinical practice in Japan. METHODS: An observational, multicenter, post-marketing, all-case surveillance was conducted for safety. Effectiveness analyses were conducted in patients aged ≤21 years and those treated with clofarabine monotherapy and combination therapy (clofarabine plus etoposide and cyclophosphamide)...
April 20, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38600749/reliability-and-validity-of-the-japanese-version-of-the-parenting-concerns-questionnaire
#5
JOURNAL ARTICLE
Misa Yanai, Maho Aoyama, Kazuhiro Kosugi, Akemi Tsumura, Erika Nakanishi, Mitsunori Miyashita
OBJECTIVE: Cancer patients with children are increasing; however, few studies have quantitatively assessed the parenting concerns of cancer patients with children. The Parenting Concerns Questionnaire was developed in the USA in 2012 and is the only instrument to measure the parenting concerns of cancer patients with children. This study aimed to develop a Japanese version of the Parenting Concerns Questionnaire and evaluate its reliability and validity. METHODS: An Internet survey was conducted among cancer patients registered with 'Cancer Parents', an Internet community site for cancer patients, who have children aged <18 years, and 174 responses were recorded...
April 10, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38594880/a-single-arm-phase-i-ii-trial-on-the-combination-of-carboplatin-nab-paclitaxel-and-avastin-as-first-line-treatment-for-advanced-non-squamous-non-small-cell-lung-cancer-torg1424-olcsg1402-carnaval
#6
JOURNAL ARTICLE
Naoyuki Nogami, Toshio Kubo, Akihiro Bessho, Makoto Sakugawa, Satoshi Ikeo, Toshihide Yokoyama, Nobuhiko Seki, Ryosuke Ochiai, Nobukazu Fujimoto, Shuji Murakami, Kyoichi Kaira, Toshiyuki Harada, Daizo Kishino, Yuichi Takiguchi, Tsuneo Shimokawa, Katsuyuki Kiura, Natsumi Yamashita, Hiroaki Okamoto
BACKGROUND: Bevacizumab with platinum doublet therapy including paclitaxel + carboplatin improves the survival of patients with non-squamous non-small cell lung cancer. However, in a previous trial (CA031), paclitaxel + carboplatin led to Grade > 3 neutropenia in a Japanese population. Nanoparticle albumin-bound paclitaxel exhibits an improved toxicity profile. We evaluated the safety, dosage and response rate of the nanoparticle albumin-bound paclitaxel + carboplatin + bevacizumab combination in a Japanese population...
April 9, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38555498/early-enteral-nutrition-and-mobilization-following-head-and-neck-surgery-with-free-flap-reconstruction
#7
JOURNAL ARTICLE
Takuya Yamamoto, Takeshi Shinozaki, Yukio Nishiya, Wataru Okano, Toshifumi Tomioka, Kazuto Matsuura, Kiichi Furuse, Azusa Oshima, Takuya Higashino, Ryuichi Hayashi
BACKGROUND: Perioperative management methods that reduce surgery-associated invasiveness and improve the quality of postoperative recovery are being promoted as enhanced recovery after surgery programs in various areas. Early enteral nutrition and mobilization are essential elements for enhanced recovery after surgery; however, their safety and feasibility are unclear in head and neck surgery with free tissue transfer reconstruction. This study aimed to clarify these uncertainties. METHODS: This is a retrospective before-after study...
March 30, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38555496/validation-and-comparison-of-prognostic-scoring-systems-in-patients-with-head-and-neck-squamous-cell-carcinoma-treated-with-nivolumab
#8
JOURNAL ARTICLE
Yukinori Takenaka, Norihiko Takemoto, Tomoyuki Otsuka, Minako Nishio, Masashi Tanida, Takashi Fujii, Kazuki Hayashi, Motoyuki Suzuki, Masashi Mori, Yoshifumi Yamamoto, Atsuhiko Uno, Hidenori Inohara
OBJECTIVE: Several scoring systems have been developed to predict prognosis in patients with refractory cancer. We aimed to validate eight scoring systems and determine the best method for predicting the prognosis of head and neck squamous cell carcinoma treated with nivolumab. METHODS: This multicentre retrospective study involved 154 patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with nivolumab between 2017 and 2020. Oncological outcomes were assessed according to the scoring systems, including MD Anderson Cancer Center + neutrophil-to-lymphocyte ratio and Hammersmith scores...
March 30, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38555494/epithelioid-hemangioendothelioma-its-history-clinical-features-molecular-biology-and-current-therapy
#9
JOURNAL ARTICLE
Kenji Tsuchihashi, Eishi Baba
Epithelioid hemangioendothelioma (EHE) is a remarkably rare tumor arising from endothelial cells that is classified as a vascular tumor in the WHO classification. The tumor is predominantly characterized by the presence of fusion genes, such as WWTR1-CAMTA1 or YAP1-TFE3, with a minority of cases exhibiting other rare fusion genes. EHE exhibits a broad age of onset, typically presenting at ~50 years, but it is not uncommon in pediatric populations. It manifests in a variety of organs, including the liver, lung, soft tissue and bone...
March 30, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38553780/comparisons-of-in-hospital-fee-and-surgical-outcomes-between-robot-assisted-laparoscopic-and-open-radical-cystectomy-a-japanese-nationwide-study
#10
JOURNAL ARTICLE
Minato Yokoyama, Wei Chen, Yuma Waseda, Motohiro Fujiwara, Daisuke Kato, Takeshi Shirakawa, Yohei Shimizu, Tsunehiro Nenohi, Yuki Matsumoto, Taisuke Okumura, Masayasu Urushibara, Masumi Ai, Kiyohide Fushimi, Takashi Fukagai, Masatoshi Eto, Yasuhisa Fujii, Kazuhiro Ishizaka
OBJECTIVE: To evaluate in-hospital fees and surgical outcomes of robot-assisted radical cystectomy (RARC), laparoscopic radical cystectomy (LRC) and open radical cystectomy (ORC) using a Japanese nationwide database. METHODS: All data were obtained from the Diagnosis Procedure Combination database between April 2020 and March 2022. Basic characteristics and perioperative indicators, including in-hospital fees, were compared among the RARC, LRC and ORC groups. Propensity score-matched comparisons were performed to assess the differences between RARC and ORC...
March 28, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38553776/preferences-of-bereaved-family-members-on-communication-with-physicians-when-discontinuing-anticancer-treatment-referring-to-the-concept-of-nudges
#11
JOURNAL ARTICLE
Saran Yoshida, Kei Hirai, Fumio Ohtake, Kento Masukawa, Tatsuya Morita, Yoshiyuki Kizawa, Satoru Tsuneto, Yasuo Shima, Mitsunori Miyashita
BACKGROUND: This study aimed to clarify the situation and evaluate the communication on anticancer treatment discontinuation from the viewpoint of a bereaved family, in reference to the concept of nudges. METHODS: A multi-center questionnaire survey was conducted involving 350 bereaved families of patients with cancer admitted to palliative care units in Japan. RESULTS: The following explanations were rated as essential or very useful: (i) treatment would be a physical burden to the patient (42...
March 28, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38535894/prognostic-impact-of-primary-tumour-location-after-curative-resection-in-stage-i-iii-colorectal-cancer-a-single-centre-retrospective-study
#12
JOURNAL ARTICLE
Manabu Inoue, Yukihide Kanemitsu, Shunsuke Tsukamoto, Konosuke Moritani, Yasuyuki Takamizawa, Hiroyuki Daiko
OBJECTIVE: The relationship of tumour site with post-recurrence course and outcome after primary surgery in resectable colorectal cancer is unclear. This study investigated the prognostic impact of primary tumour location following radical resection without preoperative treatment in Stage I-III colorectal cancer. METHODS: We analyzed 3770 patients with Stage I-III colorectal cancer who underwent curative resection at our hospital during 2000-15. We defined the right-sided colon as the cecum, ascending colon and transverse colon, and the left-sided colon as the descending colon, sigmoid and rectosigmoid junction...
March 26, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38535873/transitional-dynamics-in-oncology-clinical-trials-evaluating-the-impact-of-clinical-trials-act-on-cooperative-groups
#13
JOURNAL ARTICLE
Kenichi Nakamura, Koji Takeda, Akiko M Saito, Miho Kato, Shinya Sato, Satoshi Nakagawa, Yasuyuki Kawamoto, Eiji Oki, Isamu Okamoto, Hiroaki Okamoto, Hiroshi Katayama, Junki Mizusawa, Harumi Kaba, Taro Shibata, Haruhiko Fukuda
OBJECTIVE: large-scale multicentre clinical trials conducted by cooperative groups have generated a lot of evidence to establish better standard treatments. The Clinical Trials Act was enforced on 1 April 2018, in Japan, and it has remarkably increased the operational burden on investigators, but its long-term impact on cancer cooperative groups is unknown. METHODS: a survey was conducted across the nine major cooperative groups that constitute the Japan Cancer Trials Network to assess the impact of Clinical Trials Act on the number of newly initiated trials from fiscal year (from 1 April to 31 March) 2017 to 2022 and that of ongoing trials on 1 April in each year from 2018 to 2023...
March 26, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38525939/projection-of-the-number-of-new-cases-of-gallbladder-cancer-in-the-world
#14
JOURNAL ARTICLE
Kayo Nakata, Hadrien Charvat
No abstract text is available yet for this article.
March 24, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38521965/emerging-measurements-for-tumor-infiltrating-lymphocytes-in-breast-cancer
#15
JOURNAL ARTICLE
Rongrong Wu, Yoshiya Horimoto, Masanori Oshi, Matthew G K Benesch, Thaer Khoury, Kazuaki Takabe, Takashi Ishikawa
Tumor-infiltrating lymphocytes are a general term for lymphocytes or immune cells infiltrating the tumor microenvironment. Numerous studies have demonstrated tumor-infiltrating lymphocytes to be robust prognostic and predictive biomarkers in breast cancer. Recently, immune checkpoint inhibitors, which directly target tumor-infiltrating lymphocytes, have become part of standard of care treatment for triple-negative breast cancer. Surprisingly, tumor-infiltrating lymphocytes quantified by conventional methods do not predict response to immune checkpoint inhibitors, which highlights the heterogeneity of tumor-infiltrating lymphocytes and the complexity of the immune network in the tumor microenvironment...
March 23, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38520037/multi-institutional-study-of-osimertinib-dose-optimization-in-non-small-cell-lung-cancer-patients-with-egfr-activating-mutation-aged-70%C3%A2-years-or-older-money-trial
#16
JOURNAL ARTICLE
Yoko Tsukita, Masataka Taguri, Yasushi Goto, Yukio Hosomi, Tomonori Mizutani, Kageaki Watanabe, Kiyotaka Yoh, Satoshi Takahashi, Kaoru Kubota, Hideo Kunitoh
Osimertinib is the standard of care for patients with epidermal growth factor receptor-activating mutation-positive non-small cell lung cancer. Dose-toxicity has been previously reported, but no dose-response data within the range of 20-240 mg daily (mg/d). Thus, the current 80 mg/d dosing might be too high for elderly Japanese patients with an average body weight of only 50 kg, resulting in excessive toxicity and cost. We therefore initiated a study to investigate whether osimertinib at 40 mg/d is non-inferior to 80 mg/d in patients with advanced or recurrent epidermal growth factor receptor-activating mutation-positive non-small cell lung cancer aged ≥70 years, using a regression discontinuity design...
March 22, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38485656/association-of-lung-immune-prognostic-index-with-survival-outcomes-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-nivolumab-plus-ipilimumab
#17
JOURNAL ARTICLE
Shimpei Yamashita, Shuzo Hamamoto, Junya Furukawa, Kazutoshi Fujita, Masayuki Takahashi, Makito Miyake, Noriyuki Ito, Hideto Iwamoto, Yasuo Kohjimoto, Isao Hara
OBJECTIVE: Lung immune prognostic index is based on derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase level. Lung immune prognostic index has reported association with survival outcomes in patients with various malignancies undergoing treatment with immune checkpoint inhibitors. However, the prognostic impact of pre-treatment lung immune prognostic index in patients with metastatic renal cell carcinoma receiving nivolumab plus ipilimumab treatment remains unclear. This study examines the association between lung immune prognostic index and outcomes in this setting...
March 14, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38477568/correction-to-effectiveness-of-opioid-switching-for-dyspnea-and-its-predictors-in-cancer-patients-a-single-center-retrospective-observational-study
#18
(no author information available yet)
No abstract text is available yet for this article.
March 13, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38476004/high-efficiency-egfr-genotyping-using-cell-free-dna-in-bronchial-washing-fluid
#19
JOURNAL ARTICLE
Yoshihiko Murata, Yumi Nakajima, Yukio Sato, Nobuyuki Hizawa, Daichi Yamakawa, Daisuke Matsubara, Masayuki Noguchi, Yuko Minami
BACKGROUND: EGFR mutation testing is required for treatment of lung adenocarcinoma using epidermal growth factor receptor-tyrosine kinase inhibitor. However, the amounts of tumor tissue or tumor cells obtained by bronchoscopy are often insufficient. Bronchial washing fluid, obtained by lavage with saline after tumor biopsy or brushing, and the supernatant of bronchial washing fluid are thought to contain cell-free DNA that would be potentially applicable for EGFR testing. METHODS: From among patients with suspected adenocarcinoma or non-small cell lung carcinoma diagnosed from biopsy or surgical specimens at the University of Tsukuba Hospital between 2015 and 2019, cell-free DNAs from 80 specimens of supernatant of bronchial washing fluid (50 with EGFR mutation and 30 with wild type EGFR) and 8 blood serum samples were examined for EGFR mutation using droplet digital PCR...
March 12, 2024: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/38452123/bone-loss-over-time-and-risk-of-osteoporosis-in-advanced-pancreatic-cancer
#20
JOURNAL ARTICLE
Tsuyoshi Takeda, Takashi Sasaki, Takeshi Okamoto, Tatsuki Hirai, Takahiro Ishitsuka, Manabu Yamada, Hiroki Nakagawa, Takaaki Furukawa, Takafumi Mie, Akiyoshi Kasuga, Masato Ozaka, Naoki Sasahira
BACKGROUND: Pancreatic cancer has a high risk of developing osteoporosis. However, the impact of osteoporosis has not been well-studied. This study aimed to evaluate bone loss over time and risk of osteoporosis in patients with advanced pancreatic cancer. METHODS: We retrospectively examined consecutive patients with unresectable pancreatic cancer who had evaluable computed tomography before treatment and at 1-year follow-up. Bone mineral density at the first lumbar vertebra was measured on computed tomography, and osteoporosis was defined as bone mineral density < 135 Hounsfield units...
March 7, 2024: Japanese Journal of Clinical Oncology
journal
journal
22718
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.